Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
|
$972.49B |
$1053.75
+2.55%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$509.56B |
$214.04
+1.16%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$394.51B |
$226.96
+1.63%
|
|
AZN
AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
|
$278.47B |
$91.06
+1.37%
|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$250.53B |
$99.66
-0.64%
|
|
NVO
Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
|
$226.31B |
$50.38
+0.41%
|
|
ABT
Abbott Laboratories
Abbott competes in generic drug segments across emerging markets, aligning with the Generic Drugs theme within Established Pharmaceutical Products.
|
$218.36B |
$128.44
+2.38%
|
|
TMO
Thermo Fisher Scientific Inc.
Thermo Fisher provides companion diagnostics (e.g., Oncomine Dx tests) that inform targeted therapies.
|
$216.10B |
$567.74
-0.79%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$171.06B |
$319.44
+0.54%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
|
$149.39B |
$120.40
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$146.97B |
$26.30
+1.76%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
|
$115.90B |
$450.60
-0.32%
|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$106.68B |
$54.11
+3.24%
|
Showing page 1 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
